Synthorx (Synthorx) Interest Expense : $0.00 Mil (TTM As of Sep. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Synthorx Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Synthorx's interest expense for the three months ended in Sep. 2019 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Synthorx's Operating Income for the three months ended in Sep. 2019 was $ -13.18 Mil. Synthorx's Interest Expense for the three months ended in Sep. 2019 was $ 0.00 Mil. GuruFocus does not calculate Synthorx's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Synthorx Interest Expense Historical Data

The historical data trend for Synthorx's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Interest Expense Chart

Synthorx Annual Data

Trend

Dec16

Dec17

Dec18

Interest Expense

Synthorx Quarterly Data
	Dec16	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Interest Expense	Get a 7-Day Free Trial				-	-	-	-	-

Synthorx Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Synthorx (NAS:THOR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Synthorx's Interest Expense for the three months ended in Sep. 2019 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2019 was $-13.18 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2019 was $3.35 Mil.

Synthorx's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as

GuruFocus does not calculate Synthorx's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Synthorx (Synthorx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037

Website

http://www.synthorx.com

Executives

Powell Andrew Kenneth William	director	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver	director, officer: President and CEO	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022